Amgen

News

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

News

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.

News

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

News

The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand.

News

Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-RD.

News

Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data.